JP2003509380A5 - - Google Patents

Info

Publication number

JP2003509380A5

JP2003509380A5 JP2001523027A JP2001523027A JP2003509380A5 JP 2003509380 A5 JP2003509380 A5 JP 2003509380A5 JP 2001523027 A JP2001523027 A JP 2001523027A JP 2001523027 A JP2001523027 A JP 2001523027A JP 2003509380 A5 JP2003509380 A5 JP 2003509380A5

Authority

JP

Japan

Prior art keywords

nucleic acid

acid sequence

composition

integrin

pat

Prior art date

2000-09-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000007523 nucleic acids Chemical group 0.000 description 38
• 108091028043 Nucleic acid sequence Proteins 0.000 description 28
• 229940123038 Integrin antagonist Drugs 0.000 description 13
• 108020004707 nucleic acids Proteins 0.000 description 8
• 102000039446 nucleic acids Human genes 0.000 description 8
• 208000020832 chronic kidney disease Diseases 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 5
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 5
• 108010044426 integrins Proteins 0.000 description 5
• 102000006495 integrins Human genes 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000003446 ligand Substances 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 230000001631 hypertensive effect Effects 0.000 description 2
• 238000000034 method Methods 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 108010041012 Integrin alpha4 Proteins 0.000 description 1
• 206010038468 Renal hypertrophy Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 150000001875 compounds Chemical class 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 201000008627 kidney hypertrophy Diseases 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 201000009925 nephrosclerosis Diseases 0.000 description 1
• 206010038433 renal dysplasia Diseases 0.000 description 1
• 150000003384 small molecules Chemical group 0.000 description 1